WELLESLEY HILLS, Mass., - Joseph F. Finn, Jr., C.P.A. ("Finn"), announced today that assets of EPIX Pharmaceuticals, Inc. ("EPIX") have been assigned to him for the benefit of EPIX's creditors.
EPIX's products and services focus on the discovery and development of novel therapeutics through the use of its proprietary and highly efficient in silico drug discovery platform. The company has a pipeline of internally-discovered drug candidates currently in clinical development to treat diseases of the central nervous system and lung conditions. In addition, EPIX has several programs related to its MRI imaging business, including a commercial MRI imaging drug in Europe, (MS-325), formerly marketed as Vasorist(R), gadofosveset trisodium, by Bayer Schering Pharma.) EPIX also has collaborations with several leading pharmaceutical and research foundations.
The intellectual property, regulatory dossier, fixed assets and clinical inventory will be sold at auction, the time and date of which will be announced within a week.
No comments:
Post a Comment